Actively Recruiting
Molecular and Immunohistochemical Profiling of Tumors in Patients with Parathyroid Tumors for Evaluation of Targeted Agents
Led by M.D. Anderson Cancer Center · Updated on 2026-05-22
310
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying molecular and immunohistochemical profiling of tumors in patients with parathyroid tumors, including parathyroid carcinoma, atypical neoplasm, and parathyroid adenoma. The purpose is to better understand differences in clinical behavior and identify genes that may help improve diagnosis. This research aims to reduce inconsistencies in diagnosis, avoid unnecessary or incomplete surgery, and improve follow-up care for patients with parathyroid tumors. The study analyzes previously collected tumor tissue and blood samples from patients with parathyroid tumors. These samples are examined using immunohistochemical profiling to identify potential genes showing molecular changes similar to other cancers. This observational study involves laboratory biomarker analysis and correlative studies without new treatments or interventions. Participants are patients with available tissue or blood samples consented for research, collected from 1968 to 2015 at MD Anderson Cancer Center or collaborating sites. Researchers measure biomarker levels and identify potential diagnostic genes over a period of up to four years. No new visits or treatments are involved, as the study uses existing samples and medical data for analysis and assessment.
CONDITIONS
Brief Title
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients included have tissue or blood available from the parathyroid tumor database at MD Anderson Cancer Center or collaborating sites, collected between 1968 and 2015.
- Patients have a known diagnosis of primary hyperparathyroidism treated at MD Anderson or collaborating sites.
- Patients with consent for research use of tissue or blood samples.
- Patients with histopathological diagnosis of parathyroid carcinoma, atypical parathyroid neoplasm, or parathyroid adenoma.
- Selected patients from outside collaborations meeting tissue availability and diagnostic suitability criteria.
You will not qualify if you...
- Patients without tissue available for analysis.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to confirm sample availability and consent
Duration - Up to 4 years
Previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling to identify potential genes and molecular aberrations related to parathyroid tumors.
No visits required as analysis is performed on existing samples
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
N
Nancy D. Perrier
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here